KIN WONG: Open Payments
NPI 1962743229 · RICHWOOD, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$975 in 42 payments from 9 companies in 2025. Trend: 2023 $47 · 2024 $410 · 2025 $975
Food & beverage: $975
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 9 | $332 |
| ABBVIE INC. | 15 | $255 |
| Amgen Inc. | 5 | $111 |
| GlaxoSmithKline, LLC. | 5 | $95 |
| Indivior Inc. | 3 | $86 |
| Supernus Pharmaceuticals, Inc. | 2 | $35 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $27 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $14 |
Products named: VRAYLAR, FARXIGA, TRELEGY ELLIPTA, SUBLOCADE, REPATHA, AIRSUPRA, BREZTRI, Qelbree.
Industry payments across TX — which companies pay providers there.
